8-K: InMed Pharmaceuticals Faces Nasdaq Delisting, Appeals Decision and Secures Hearing Date

InMed Pharmaceuticals has appealed a Nasdaq delisting notice and secured a hearing to present its plan to regain compliance with the minimum bid price rule.

Summary

• InMed Pharmaceuticals received a delisting notice from Nasdaq because its share price did not meet the minimum $1.00 bid price requirement.
• The company had previously been granted an extension until September 16, 2024, to regain compliance.
• InMed has appealed the delisting notice and requested a hearing before the Nasdaq Listing Qualifications Panel.
• The hearing is scheduled for October 31, 2024.
• The appeal has temporarily halted any delisting or suspension actions.
• The Panel has the authority to grant InMed up to an additional 180 days to regain compliance, impose stricter listing criteria, or proceed with delisting.
• There is no guarantee that the Panel will grant an extension or that the outcome will be favorable for InMed.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and uncertainty surrounding the appeal outcome. While the company has taken steps to appeal, the risk of delisting remains significant.

Positives

• InMed has successfully appealed the delisting notice, preventing immediate delisting.
• The company has secured a hearing date with the Nasdaq Listing Qualifications Panel.
• The Panel has the authority to grant an additional 180-day extension for compliance.

Negatives

• InMed failed to meet the minimum $1.00 bid price requirement by the September 16, 2024 deadline.
• The company received a delisting notice from Nasdaq.
• There is no guarantee that the Panel will grant an extension or that the outcome will be favorable.

Risks

• The Nasdaq Listing Qualifications Panel may not grant an extension for InMed to regain compliance.
• The Panel could impose stricter listing criteria on the company.
• There is a risk that InMed's shares could be suspended or delisted from Nasdaq.
• The outcome of the hearing and appeal is uncertain.

Future Outlook

The company's future on the Nasdaq exchange is uncertain, pending the outcome of the hearing and appeal. There is a possibility of an additional 180-day extension, but also the risk of delisting.

Management Comments

• InMed has timely requested a hearing before the Nasdaq Listing Qualifications Panel to appeal the delisting notice.
• The company will present its plan to regain and sustain compliance with the minimum bid price rule.

Industry Context

This situation is not uncommon for smaller pharmaceutical companies, as maintaining a minimum share price can be challenging, especially during periods of market volatility or when facing development setbacks. Other companies in the sector may face similar challenges.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, particularly regarding minimum bid price requirements.
• Companies like Cassava Sciences (SAVA) and Amylyx Pharmaceuticals (AMLX) have faced similar scrutiny, although their situations and outcomes may differ.
• The outcome for InMed will depend on the strength of their plan to regain compliance and the Panel's assessment of their prospects.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's reputation and ability to attract future investment could be negatively impacted.

Next Steps

• InMed will attend the hearing before the Nasdaq Listing Qualifications Panel on October 31, 2024.
• The company will present its plan to regain compliance with the minimum bid price rule.
• The Panel will make a decision regarding the appeal and potential extension.

Key Dates

Keywords

Nasdaq, Delisting, Minimum Bid Price, Compliance, Appeal, Hearing, Listing Qualifications Panel, INM, Pharmaceuticals